Toronto, Ontario–(Newsfile Corp. – June 10, 2021) – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, and Professor Celia Morgan, Head of Awakn’s Ketamine-Assisted Psychotherapy for Addiction Practice, will participate in H.C. Wainwright’s Psychedelics in Psychiatry and Beyond Virtual Conference panels on Thursday, June 17, 2021.
H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Date: Thursday, June 17th
Time: 9:00 – 10:00 a.m. ET
Speaker: Anthony Tennyson
Panel: Disruptive Psychopharmacology – An Introduction to Psychedelics and the Coming Revolution in Psychiatry
Time: 2:00 – 3:30 p.m. ET
Speaker: Professor Celia Morgan
Panel: The Patient Experience and Commercial Considerations when Launching Psychoactive Agents in Psychiatry
To register for the webcast of each panel please visit here.
For more information regarding the conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact KCSA Strategic Communications at Awakn@KCSA.com or your H.C. Wainwright representatives directly.
Media enquiries:
America and Canada: KCSA Strategic Communications – Anne Donohoe (Awakn@KCSA.com)
Rest of World: ROAD Communications – Paul Jarman (paul@roadcommunications.co.uk / Anna Ramsey (anna@roadcommunications.co.uk)
Investor enquiries:
KCSA Strategic Communications – Valter Pinto / Tim Regan (Awakn@KCSA.com)
About Awakn Life Sciences Inc.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction. Awakn is integrating psychedelic medicine into mainstream healthcare through Research, Digital, Clinics, and Ecosystems.
www.awaknlifesciences.com | Twitter | LinkedIn | Facebook
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87169
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…